Revenue from Contract with Customer [Text Block]

Revenue

Disaggregation of revenue

Disaggregated revenue by primary geographical markets and major goods and service lines are as follows:


	Reportable Segments
	Three Months Ended
	September 28, 2025						September 29, 2024
	Life Sciences		Diagnostics		Total		Life Sciences		Diagnostics		Total
	(In thousands)
Primary geographical markets
Americas	$	178,087	$	129,190	$	307,277	$	185,476	$	116,849	$	302,325
Europe	83,332		119,065		202,397		75,115		106,923		182,038
Asia	81,403		107,872		189,275		78,209		121,477		199,686
	$	342,822	$	356,127	$	698,949	$	338,800	$	345,249	$	684,049

Major goods/service lines
Life Sciences Solutions	$	290,541	$	—	$	290,541	$	295,455	$	—	$	295,455
Software	52,281		—		52,281		43,345		—		43,345
Immunodiagnostics	—		212,739		212,739		—		211,566		211,566
Reproductive health	—		143,388		143,388		—		133,683		133,683
	$	342,822	$	356,127	$	698,949	$	338,800	$	345,249	$	684,049


	Reportable Segments
	Nine Months Ended
	September 28, 2025						September 29, 2024
	Life Sciences		Diagnostics		Total		Life Sciences		Diagnostics		Total
	(In thousands)
Primary geographical markets
Americas	$	559,437	$	376,049	$	935,486	$	551,843	$	352,619	$	904,462
Europe	243,652		344,169		587,821		227,123		318,065		545,188
Asia	246,026		314,662		560,688		244,873		331,131		576,004
	$	1,049,115	$	1,034,880	$	2,083,995	$	1,023,839	$	1,001,815	$	2,025,654

Major goods/service lines
Life Sciences Solutions	$	875,046	$	—	$	875,046	$	884,849	$	—	$	884,849
Software	174,069		—		174,069		138,990		—		138,990
Immunodiagnostics	—		629,119		629,119		—		613,479		613,479
Reproductive health	—		405,761		405,761		—		388,336		388,336
	$	1,049,115	$	1,034,880	$	2,083,995	$	1,023,839	$	1,001,815	$	2,025,654

Contract Balances

Unbilled receivable and Contract assets: The timing of revenue recognition may differ from the timing of customer billing. When revenue is recognized prior to billing and the right to the amount due from customers is conditioned only on the passage of time, the Company records an unbilled receivable on its consolidated balance sheets. The unbilled receivables are classified as either current in “Accounts receivable, net” or as long-term in “Other assets, net” in the condensed consolidated balance sheets. Unbilled receivables totaled $95.5 million and $80.6 million at September 28, 2025 and December 29, 2024, respectively, primarily related to the Life Sciences software business. The Company had no material contract assets as of September 28, 2025 and December 29, 2024.

Deferred revenue and Customer deposits: Deferred revenue is recorded when revenue is recognized subsequent to customer invoicing. Deferred revenue is classified as either current in “Accrued expenses and other current liabilities” or as long-term in “Other long-term liabilities” in the condensed consolidated balance sheets based on the timing of when the Company expects to recognize revenue. Substantially all of the deferred revenue is expected to be recognized in revenue within 12 months of the balance sheet date, and has been classified within accrued expenses and other current liabilities. The deferred revenue balance is primarily related to the Company’s software as a service offerings, maintenance contracts and prepaid storage arrangements. Deferred revenue totaled $224.0 million and $212.8 million at September 28, 2025 and December 29, 2024, respectively. The Company also had customer deposits received in advance of the transfer of control totaling $19.5 million at September 28, 2025 and December 29, 2024. The Company expects that these customer deposits will be recognized in revenue within three months of the balance sheet date.

Transaction price allocated to the remaining performance obligations

The Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.